Clinical evidence can convince surgeons without answering the question that often determines hospital adoption: what is this innovation worth economically?
A small medtech company gets the kind of result most companies never get: a landmark clinical study, published in one of the field's top journals and picked up by international media. The surgeons are convinced. The science is undeniable.
And the person who actually signs off on the purchase, a hospital administrator focused on budgets and operating room time, has a completely different question that the clinical paper never answers.
Clinical evidence and economic evidence do different jobs
The surgeon wants to know the technology works. The hospital administrator wants to know what it is worth, specifically in avoided costs, freed-up operating room time and fewer repeat procedures.
The same clinical evidence can help answer both questions, but almost never in the same document, written for the same reader.
One argument establishes clinical value. The other translates that value into the operational and financial terms that influence hospital adoption.
Why the economic value story often lags behind clinical evidence
For a small, scientifically driven medtech team, the instinct after a major publication is to keep building on the clinical momentum: more studies, more evidence and more surgeon champions.
The economic argument for the hospital budget holder who actually approves the purchase order gets built later, if at all, even though it is frequently the harder blocker to adoption, not the clinical case.
Strong clinical evidence may prove that an innovation works. It does not automatically explain the impact on hospital costs, operating room efficiency or the wider procurement decision.
Turn clinical evidence into a separate hospital economic case
The answer is not a longer clinical paper.
It is a separate, deliberately built hospital economic value case that translates the same evidence into cost-avoidance and efficiency terms a hospital decision-maker can act on.
That case can sit alongside a structured customer reference story from an early adopting hospital, showing not only the clinical outcome but also what adoption means in practice.
Together, they give hospital decision-makers a clearer view of clinical value, operational impact and financial relevance without asking one document to do every job.
The question medtech teams should ask
The question is no longer simply: “Is our clinical evidence strong enough?”
If the clinical case is already compelling, the more important question becomes: “Have we clearly explained what this is worth to the person who has to approve the investment?”
That is often the missing step between clinical success and broader hospital adoption.
From clinical success to Customer Reference Marketing
This is part of our Customer Reference Marketing work at Living Stone: turning strong clinical results and an early hospital relationship into a structured economic case and customer reference story that reaches the person who signs the purchase order, not only the person who runs the procedure.
If this sounds familiar, we'd like to hear about it. See how we approach Customer Reference Marketing.
